

## PRESS RELEASE

**RENAISSANCE, AURORA AND THE PAVESE FAMILY  
ANNOUNCE THEIR PARTNERSHIP IN GENETIC**

- Renaissance Partners and Aurora Growth Capital will acquire the entire share capital of Genetic from CVC and the Pavese Family, which will re-invest in a 50-50 partnership transaction
- Genetic is the leading Italian CDMO in the respiratory and ophthalmic therapeutic areas, which internally develops and manufactures complex pharma dossiers, reaching more than 40 international markets and nearly 5 million patients worldwide
- The Pavese Family will continue to lead the business with Rocco Pavese as CEO and Francesca Pavese as Vice President of the Board of Directors and responsible for the Business Development initiatives

*Milan, May 20, 2025* – Renaissance Partners (“Renaissance”) and Aurora Growth Capital (“Aurora”) signed a binding agreement to acquire the entire share capital of Genetic S.p.A. (“Genetic” or the “Company”) from CVC Strategic Opportunities (“CVC”) and Rocco, Francesco and Francesca Pavese (the “Pavese Family”). The Pavese Family will re-invest alongside Renaissance and Aurora in a 50-50 partnership.

Founded in 2000 by Rocco Pavese and headquartered in Fisciano (Salerno, Italy), Genetic is a pharma Contract Development and Manufacturing Organization (“CDMO”) with a differentiated positioning in the development and manufacturing of complex generic molecules, boasting a top-notch portfolio in the respiratory and ophthalmic therapeutic areas. The Company combines proprietary dossier development with advanced manufacturing – including Blow-Fill-Seal (BFS) technology – to deliver sterile monodose preservative-free formats, inhalers (pMDI and DPI), nasal sprays as well as monodose and multidose (including preservative-free) eye drops. Genetic’s focus is on technically challenging – hard-to-develop and hard-to-make – products in both oral solid and liquid formulations.

Genetic operates globally, serving a diversified B2B customer base – including blue-chip pharma companies – and exports more than 40% of its products across over 40 countries. The company reaches nearly 5 million patients annually worldwide, creating meaningful social value by improving access to affordable, user-friendly therapies—primarily targeting vulnerable populations such as children and the elderly – thereby contributing to broader healthcare coverage and affordability. The Genetic group is also active in the direct sale of pharma drugs to pharmacies and wholesalers through its subsidiary Genetic Pharma and in the development and manufacturing of supplements and medical devices through its subsidiary Genelife.

Rocco Pavese, founder and CEO of Genetic since 2000, together with Francesca Pavese, responsible for Genetic’s Business Development and Internationalization, will continue to lead the Company through this new stage of expansion.

The partnership between Renaissance, Aurora and the Pavese Family is aimed at unlocking the next phase of Genetic’s growth. The strategic plan envisages capacity expansion – including the building of a new state-of-the-art plant in Fisciano (with a relevant investment on the territory in technology and human capital to grow the workforce) – to capitalize on favourable market tailwinds supporting both the existing portfolio and a compelling pipeline of new products. The goal is to further accelerate on the successful growth path achieved to date and further penetrate selected international markets.

**Rocco Pavese, CEO of Genetic**, commented: “We are excited to begin a new phase of development for Genetic alongside Renaissance Partners and Aurora Growth Capital. The Genetic group is currently recognized internationally as a reliable and high-quality partner in the pharmaceutical, medical device and nutraceutical sectors, especially thanks to the outstanding value of our team of professionals who collaborate and put their daily efforts to achieve increasingly ambitious goals. Our commitment will remain focused on the research and development of complex and cutting-edge therapeutic solutions that can improve patients’ quality of life, in line with our entrepreneurial identity underpinned by innovation”.

**Francesca Pavese, Head of BD and Internationalization at Genetic**, added: “We look to the future with renewed confidence. We will continue to devote ourselves with commitment and passion towards the development

of our products pipeline and investments in infrastructure and new technologies, with the goal of further strengthening our established partnerships and seizing growth opportunities alongside our current and future commercial partners".

**Luca Deantoni and Giovanni Camisassi, Partners of Renaissance**, commented: "We are honoured that the Pavese Family has chosen us as their partner for the next phase of Genetic's expansion. This investment is fully aligned with our strategy of partnering with ambitious founding families and strong management teams to invest in Italian champions with solid fundamentals, proven financial performance and tangible contribution to society. Genetic stands out for its distinctive R&D capabilities, strong industrial know how and profound social impact, developing generic drugs that treat debilitating and life-impacting conditions, ultimately improving patients' wellbeing and healthcare affordability. With our expertise in the pharmaceutical sector, we look forward to supporting the Company's growth, including its expansion into new markets and the development of its pipeline of high-impact molecules".

**Giacinto d'Onofrio, Managing Partner of Aurora**, concluded: "Genetic is a top-notch CDMO, with high profitability and cash flow as well as a relevant historical growth. We believe that the Company is very well positioned to continue its growth path, thanks to its strong competitive positioning, pipeline of new products and a number of already identified strategic initiatives. We also believe that Genetic has the right leadership team to manage the next Company's phase, and we are ready to give our contribution as new shareholders to achieve Genetic's business plan targets".

Renaissance and Aurora were assisted by Mediobanca, BNP Paribas and JP Morgan (financial advisors), Vitale (debt advisor), Gatti Pavesi Bianchi Ludovici (legal advisor for the acquisition and the financing), Paul Weiss (legal advisor for financing – English law), Boston Consulting Group and IQVIA Italia (business), Deloitte (accounting and tax), EFESO (operations) and EY (sustainability and ESG). The Pavese family was assisted by Alma LED (legal and tax). The transaction will be funded by Blackstone and CVC Credit, assisted by GattaiPedersoli (legal). Subject to the satisfaction of customary conditions, the closing of the transaction is expected to occur in Q3 2025.

#### About Renaissance Partners

Renaissance Partners is an investment firm with a focus on family-owned mid-market companies primarily headquartered in Italy. Renaissance Partners leverages its industrial expertise across four core investment themes: healthcare, information technology, sustainability and specialized industrials. Renaissance currently manages over €2.8 billion in commitments and is invested in 12 companies with an aggregate turnover of approximately €6 billion. For further information please refer to the [Renaissance website](#).

#### About Aurora Growth Capital

Aurora invests in leading Italian SMEs, niche market leaders with high added value and growth potential. Aurora's investment strategy focuses on five verticals: made in Italy, healthcare, environmental & sustainability, tech growth & digital transformation, and specialized industrial manufacturing & business services. Aurora has currently 12 portfolio companies with an aggregate turnover of approximately €2.6 billion. For further information please refer to the [Aurora Growth Capital website](#).



Ph. +39 02 03005343  
Mob. +39 375 6408862  
Mail. [info@giovannamarchicomunicazione.com](mailto:info@giovannamarchicomunicazione.com)

20122 Milano - Via Conchetta, 4  
00195 Roma - Via Costantino Morin, 44

**Giovanna Marchi**  
Mob. +39 335 711 7020  
[g.marchi@giovannamarchicomunicazione.com](mailto:g.marchi@giovannamarchicomunicazione.com)

**Andrea Giannotti**  
Mob. +39 347 355 5096  
[giannotti@reenewpr.uk](mailto:giannotti@reenewpr.uk)